Leonard Zon

An HSCI approach to rhabdomyosarcoma

September 29, 2013

Rhabdomyosarcoma is a rare childhood cancer that arises in muscle stem cells. Between 250-350 cases are treated each year. The disease most commonly begins as a noticeable swelling in the arms, legs, head, neck, or groin, and is treated by surgical removal of the tumor, as well as chemotherapy or irradiation. Currently, about 80% of patients diagnosed with rhabdomyosarcoma survive, as the disease is often caught early enough for intervention.

In this feature, one senior investigator, one junior investigator, and one postdoctoral researcher—all working...

Read more about An HSCI approach to rhabdomyosarcoma

David Scadden, MD, and Leonard I. Zon, MD, win Hematology Society awards

July 22, 2010

"The American Society of Hematology (ASH), the world’s largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be presented at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando."

Two HSCI Principal Faculty members are among those receiving awards.

"David T. Scadden, MD, of the Massachusetts General Hospital and the Harvard Stem Cell Institute, Boston, MA, will be presented with the 2010 Dameshek Prize for his landmark...

Read more about David Scadden, MD, and Leonard I. Zon, MD, win Hematology Society awards